A phase 2 trial of weekly nab-paclitaxel for advanced non-small cell lung cancer without EGFR mutation nor ALK fusion gene in salvage setting
Phase 2
- Conditions
- Advanced non-small cell lung cancer without EGFR mutation nor ALK fusion gene
- Registration Number
- JPRN-UMIN000016173
- Lead Sponsor
- Kurashiki Central Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
Not provided
Exclusion Criteria
1)symptomatic brain metastasis 2)massive or uncontrolable pleural effusion 3)less than two weeks after palliative irradiation for bone metastases or the brain metastasis except the primary tumor 4)previous chemotherapy with paclitaxel or nab-paclitaxel 5)active concomitant malignancy 6)active infectious disease 7)severe comorbidity 8)history of severe drug allergy 9)continuous steroid therapy 10)phsychiatry disease 11)pregnant or lactating woman 12)HBs antigen positive 13)Peripheral neuropathy>CTCAE Grade2 14)interstitial pneumoia or active lung fibrosis on chest X-ray 15)Otherwise determined by the investigator to be unsuitable as a subject in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method